Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female ≥ 18 to ≤ 75 years of age
Low density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and \< 190 mg/dL
Framingham risk score of 10% or less
Fasting triglycerides \< 400 mg/dL
You may not be if
History of coronary heart disease
New York Heart Association (NYHA) II - IV heart failure
Uncontrolled cardiac arrhythmia
Uncontrolled hypertension
Clareo Health | Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
